Clinical Trial Update: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC [Phase 3]

View source ↗

Summary

This entry reports a Phase III trial evaluating toripalimab in combination with lenvatinib for advanced hepatocellular carcinoma, which is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING